Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 2fludarabine phosphate 2fludarabine 2aldesleukin 2Cyclophosphamide 2rocakinogene sifuplasmid 1durvalumab 1VGX-3100 1Surveys and Questionnaires 1Sildenafil Citrate 1Paclitaxel 1MEDI0457 1Interleukin-2 1Immunoglobulin G 1Ifosfamide 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Fentanyl 1Disulfides 1Cisplatin 1Alprostadil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Penile Neoplasms × MEDI0457 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡